2020
DOI: 10.1007/s40267-020-00767-1
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacotherapeutic considerations for systemic rheumatic diseases amid the COVID-19 pandemic: more questions than answers

Abstract: Thus far, associations between the presence of systemic rheumatic disease and an increased risk of novel coronavirus disease 2019 (COVID-19) acquisition or a worse prognosis from COVID-19 have not been conclusive. It is not known for certain if there is an association between any pharmacological agent used for rheumatologic treatment, including biological and non-biological disease-modifying antirheumatic drugs (DMARDs), and an increased risk of COVID-19 acquisition or adverse outcomes from COVID-19, although … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 39 publications
0
1
0
Order By: Relevance
“…At the moment, there is no universal guideline for the continuation of immunosuppressive drugs during a COVID-19 infection [ 17 ]. This decision should be made for each patient individually.…”
Section: Resultsmentioning
confidence: 99%
“…At the moment, there is no universal guideline for the continuation of immunosuppressive drugs during a COVID-19 infection [ 17 ]. This decision should be made for each patient individually.…”
Section: Resultsmentioning
confidence: 99%